SeaStar Medical Completes Enrollment of SCD 005 Trial to Evaluate Safety of SCD in AKI and/or ARDS Patients with COVID-19
SeaStar Medical Completes Enrollment of SCD 005 Trial to Evaluate Safety of SCD in AKI and/or ARDS Patients with COVID-19

SeaStar Medical recently completed enrollment of its SCD-005 clinical trial to demonstrate the safety of Selective Cytopheretic Device (SCD) in acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS) with COVID-19 infection. This...

Read More Patient perspectives on the state of patient access